Multidisciplinary Symposium on the Immunological Consequences of Targeted Immune Therapies - ESID 2021

Modern treatment of inflammatory disease or malignancy increasingly targets specific elements of the immune system through cellular therapies (eg CAR-T cells), targeted monoclonal antibodies directed against specific cytokines or receptors (eg anakinra) or cells (eg alemtuzumab) or small molecules targeting signaling pathways (eg JAK inhibitors). Whilst effective at treating the disease, the unintended effect of these therapies may lead to phenocopies of primary immunodeficiencies, which may not be noticed, resulting in secondary immunodeficiencies.